The Evolving Renal Cell Carcinoma Treatment Landscape: 2023 and Beyond
Monty Pal, MD discusses the implications of updated NCCN guidelines on mRCC treatment selection and sequencing in 2023 as well as unmet needs in the mRCC treatment landscape.
Utilizing Lenvatinib Plus Everolimus in the Metastatic Renal Cell Carcinoma Setting
A closer look at lenvatinib plus everolimus in patients with advanced renal cell carcinoma, touching on dose-related toxicities.
Data-Informed Discussion of Tivozanib in Patients with Metastatic Renal Cell Carcinoma
Thoughtful discussion of study data supporting the use of tivozanib in patients with metastatic renal cell carcinoma, in the relapsed/refractory setting.
Factors Influencing Treatment Selection and Sequencing in Advanced Renal Cell Carcinoma
Dr. Pal discusses clinical insights concerning treatment selection and sequencing in patients with metastatic renal cell carcinoma.
A 71-Year-Old Woman with Relapsed-Refractory (R/R) Metastatic Clear Cell Renal Cell Carcinoma
Monty Pal, MD, introduces a metastatic clear cell renal cell carcinoma (ccRCC) patient case and shares how he may approach treatment.
Important Clinical Questions to Address in GI Cancers
Sumanta K. Pal, MD, explains what gastrointestinal cancer research needs to focus on in the near future.
Sequencing Abiraterone and Enzalutamide in mCRPC
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Adjuvant Therapy for Renal Cell Carcinoma
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).